Intra-Cellular Therapies Inc (ITCI)
85.45
-0.19
(-0.22%)
USD |
NASDAQ |
Nov 21, 16:00
85.51
+0.06
(+0.07%)
After-Hours: 20:00
Intra-Cellular Therapies Enterprise Value: 8.053B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 8.053B |
| November 20, 2024 | 8.073B |
| November 19, 2024 | 7.830B |
| November 18, 2024 | 7.737B |
| November 15, 2024 | 7.837B |
| November 14, 2024 | 8.284B |
| November 13, 2024 | 8.346B |
| November 12, 2024 | 8.375B |
| November 11, 2024 | 8.701B |
| November 08, 2024 | 8.672B |
| November 07, 2024 | 8.589B |
| November 06, 2024 | 8.476B |
| November 05, 2024 | 8.454B |
| November 04, 2024 | 8.129B |
| November 01, 2024 | 8.168B |
| October 31, 2024 | 7.978B |
| October 30, 2024 | 8.055B |
| October 29, 2024 | 7.130B |
| October 28, 2024 | 7.138B |
| October 25, 2024 | 7.029B |
| October 24, 2024 | 7.011B |
| October 23, 2024 | 6.945B |
| October 22, 2024 | 7.165B |
| October 21, 2024 | 7.146B |
| October 18, 2024 | 7.297B |
| Date | Value |
|---|---|
| October 17, 2024 | 7.333B |
| October 16, 2024 | 7.059B |
| October 15, 2024 | 6.913B |
| October 14, 2024 | 6.820B |
| October 11, 2024 | 7.024B |
| October 10, 2024 | 6.796B |
| October 09, 2024 | 6.757B |
| October 08, 2024 | 6.667B |
| October 07, 2024 | 6.539B |
| October 04, 2024 | 6.720B |
| October 03, 2024 | 6.652B |
| October 02, 2024 | 6.691B |
| October 01, 2024 | 6.694B |
| September 30, 2024 | 6.749B |
| September 27, 2024 | 6.722B |
| September 26, 2024 | 6.713B |
| September 25, 2024 | 6.836B |
| September 24, 2024 | 6.957B |
| September 23, 2024 | 6.988B |
| September 20, 2024 | 7.178B |
| September 19, 2024 | 7.110B |
| September 18, 2024 | 6.870B |
| September 17, 2024 | 6.914B |
| September 16, 2024 | 6.930B |
| September 13, 2024 | 6.942B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
254.07M
Minimum
Nov 25 2019
8.701B
Maximum
Nov 11 2024
3.792B
Average
4.014B
Median
Aug 26 2022
Enterprise Value Benchmarks
| Ionis Pharmaceuticals Inc | 4.154B |
| AbbVie Inc | 367.30B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.32M |
| Revenue (Quarterly) | 175.16M |
| Total Expenses (Quarterly) | 214.01M |
| EPS Diluted (Quarterly) | -0.25 |
| Gross Profit Margin (Quarterly) | 91.26% |
| Profit Margin (Quarterly) | -15.03% |
| Earnings Yield | -1.02% |
| Normalized Earnings Yield | -1.018 |